Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 13, 2021 16:30 ET | Source: MediciNova, Inc.

MediciNova Reports First Quarter 2021 Financial Results and Business Update

- Completed $20M private placement financing with 3D Investment Partners - - Entered into partnership with BARDA to evaluate MN-166 for chlorine gas-induced lung damage such as acute respiratory...
May 05, 2021 20:00 ET | Source: MediciNova, Inc.

MediciNova Receives a Notice of Intention to Grant for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Europe

LA JOLLA, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
April 22, 2021 06:30 ET | Source: MediciNova, Inc.

MediciNova Receives Gene Therapy Milestone Payments

LA JOLLA, Calif., April 22, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
April 19, 2021 06:30 ET | Source: MediciNova, Inc.

MediciNova to Participate in the B. Riley Neuroscience Conference

LA JOLLA, Calif., April 19, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
April 15, 2021 06:30 ET | Source: MediciNova, Inc.

MediciNova to Participate in the UBS Global Healthcare Virtual Conference

LA JOLLA, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
March 09, 2021 16:00 ET | Source: MediciNova, Inc.

MediciNova Announces Partnership with BARDA to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury

LA JOLLA, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
March 08, 2021 06:30 ET | Source: MediciNova, Inc.

MediciNova to Participate in M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference

LA JOLLA, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
March 03, 2021 06:30 ET | Source: MediciNova, Inc.

MediciNova Announces Update on SARS-CoV-2 Vaccine for COVID-19

LA JOLLA, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
January 31, 2021 18:00 ET | Source: MediciNova, Inc.

MediciNova Announces Closing of US$20 Million Private Placement Transaction

LA JOLLA, Calif., Jan. 31, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
January 18, 2021 18:00 ET | Source: MediciNova, Inc.

MediciNova Receives Notice of Allowance for New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Japan

LA JOLLA, Calif., Jan. 18, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right